Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] LIG D&A (079550) – iM Securities | Export Pipeline · CapEx & Hiring Expansion · Global Air Defense Growth / 2026-08-07 Research
  • [Research] Samsung SDI (006400/KS) – SK Securities | Prominent Base Effects · Conservative CapEx Management · Compelling Valuation / 2026-02-03 Research
  • [IR] SK hynix (000660 / SKHY) – Q4 2023 Earnings Presentation / 2024-01-25 IR Room
  • [Research] SK hynix (000660 / SKHY) – DS Investment | Server Memory Demand · HBM3E Pricing · Margin Expansion / 2026-01-30 Research
  • [IR] SK hynix (000660 / SKHY) – Q1 2025 Earnings Presentation / 2025-04-24 IR Room
  • [Research] Samsung Biologics (207940) – iM Securities | New Plant Operations · PolyPeptide Acquisition · Portfolio Diversification / 2026-07-24 Research
  • [Research] SK hynix (000660 / SKHY) – SK Securities | AI Memory · NAND Tiering · Earnings Re-rating / 2026-02-24 Research
  • [Research] SK hynix (000660 / SKHY) – IBK Securities | AI Servers · Full-Stack Memory · NAND Demand / 2026-04-24 Research

[Research] SK hynix (000660 / SKHY) – Shinhan | Memory ASP · Supply Tightness · Pricing Power / 2026-01-30

Posted on January 30, 2026August 24, 2026 By ksb220805@gmail.com

Market: KOSPI (000660)

Brokerage : Shinhan Securities

Analyst : Hyungtae Kim (RA: Hyesus Song)

Investment Rating : BUY (Maintained)

Target Price : 1,300,000 KRW (Raised)

Core Momentum : Severe supply-demand imbalances and depleted inventories are expected to sustain broad-based memory ASP increases, strengthening supplier pricing power and driving rapid margin and earnings expansion across DRAM and NAND.

📊 1. [Valuation & Key Financial Metrics]

  • Target Price: 1,300,000 KRW (Based on Target P/B 3.5x applied to 2026F BPS of 345,704 KRW, Raised)
  • Investment Rating: BUY (Maintained)
  • 2026F Financial Outlook: Revenue 211.67 trillion KRW, Operating Profit 143.42 trillion KRW, Net Income 123.22 trillion KRW
  • Valuation Multiples: PER 4.9x, PBR 2.5x, EV/EBITDA 3.4x, ROE 68.3% (Based on 2026F)

🚀 2. [Market Opportunities & Business Outlook]

  • 4Q25 Review: Revenue reached 32.8 trillion KRW (+34.3% QoQ) and operating profit hit 19.2 trillion KRW (+68.4% QoQ), beating consensus estimates (Revenue 31.3 trillion KRW, OP 16.7 trillion KRW). DRAM operating margin hit ~68%, with NAND approaching 30%. Estimated B/G for DRAM/NAND stood at +0.7%/+10%, and ASP growth at +24.7%/+30.4%, beating prior expectations.
  • 1Q26 Preview: Operating profit is projected at 28.3 trillion KRW (+47.5% QoQ) on revenue of 44.1 trillion KRW (+34.4% QoQ). With limited B/G growth, ASPs are expected to surge by ~36%, driving operating margins up to 72.1% for DRAM and 41% for NAND.
  • Industry & LTA Dynamics: Amid reaffirmed hyperscaler investment commitments, supplier-led Long-Term Agreements (LTAs) are under discussion. Despite efforts to maximize output and enhance processes, tight supply conditions are expected to persist throughout the year with inventories near rock bottom.
  • Growth Drivers & Returns: Outlines reviewed shareholder return initiatives, business expansion via the AI subsidiary (AI Co.), and upcoming high-value product diversification directions for the second half.

📝 Editor’s Comment (Perspective & Thesis Verification)

The analyst views SK hynix as an enterprise capturing explosive earnings growth fueled by severe supply shortages and broad ASP uptrends across all memory products, while leveraging strong cash generation to review shareholder remuneration and pursue high-value portfolio expansion. The analyst highlights earnings level-ups and supplier pricing power.

To verify this investment thesis, one should track whether 1Q26 results hit the projected revenue of 44.1 trillion KRW and operating profit of 28.3 trillion KRW with expanded margins, if supplier-driven LTA contracts are successfully formalized, and how high-value product diversification directions and shareholder return policies unfold. These indicators can be monitored through upcoming quarterly reports and regulatory filings via DART.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] SK hynix (000660 / SKHY) – iM Securities | Fixed Memory Pricing · Supply Shortage · Earnings Growth / 2026-01-30
Next Post: [Research] SK hynix (000660 / SKHY) – Eugene Investment | HBM · eSSD · Margin Expansion / 2026-01-30

Related Posts

  • [Research] LIG D&A (079550) – Hana Securities | 4Q25 Miss · Solid Order Backlog · Medium-to-Long-term Fundamentals / 2026-02-19 Research
  • [Research] Samsung Electro-Mechanics (009150) – Hana Securities | AI MLCC Shortage · Price Cycle · High-End Margin / 2026-07-31 Research
  • [Research] Celltrion (068270) – Yuanta Securities | New Biosimilar Growth · Facility Expansion · CMO Capacity Readiness / 2026-05-07 Research
  • [Research] SK hynix (000660 / SKHY) – Kyobo | Agentic AI · High-Value Memory · Pricing Momentum / 2026-04-24 Research
  • [Research] Alteogen (196170) – Hana Securities | ALT-B4 Differentiation Potential · Enhanze Biosimilar Concerns Dispelled · Qlex Revenue Visibility / 2026-07-15 Research
  • [Research] Hanwha Ocean (042660) – Eugene | High-Price Order Mix · Merchant Margin Continuity · Special Ship Pipeline / 2026-07-28 Research
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Big Tech Backlogs · Memory Supply Tightness · Earnings Growth / 2026-07-14 Research
  • [Research] Alteogen (196170) – Hana Securities | Steady Milestone Inflows · Interpreting GSK’s Enhanze Deal · PGR Final Ruling Catalysts / 2026-05-13 Research
  • [Research] LIG D&A (079550) – SK Securities | CapEx Expansion · Global Interceptor Shortage · Earnings Quality / 2026-08-10 Research
  • [Research] Samsung SDI (006400) – Mirae Asset Securities | Commencing Customer T ESS Business (Estimated) · SDC Asset Utilization · Valuation Gap Narrowing / 2026-02-03 Research
  • [Research] LigaChem Biosciences (141080) – Mirae Asset Securities | Clinical Readouts · Pipeline Valuation · SOTP / 2026-01-26 Research
  • [Research] LigaChem Biosciences (141080) – Shinhan Securities | ConjuALL · Clinical Milestones · Big Pharma L/O / 2026-03-24 Research
  • [Research] Hanwha Ocean (042660) – Eugene | High-Price Order Mix · Merchant Margin Continuity · Special Ship Pipeline / 2026-07-28 Research
  • [Research] Celltrion (068270) – DS Investment & Securities | 2Q26 Re: Steep Growth Exceeds Expectations · New Biosimilars Surge · Large-Cap Top Pick / 2026-07-28 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme